申请人:Nanjing TransThera Biosciences Co. Ltd.
公开号:US20190040064A1
公开(公告)日:2019-02-07
The present invention relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt and stereoisomer thereof, wherein R1, R2, X, Y, P, W, and Ar are as defined in the description. The compound of formula (I) of the present invention can be used in the preparation of a drug for treating cancers mediated by abnormality of multi-kinases. Also provided is a crystal form I of a compound 4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b]pyrido[4,3-e][1,4]diazepin-8-yl)morpholine, wherein in an X-ray powder diffraction pattern of crystal form I, there are characteristic peaks at 7.4±0.20, 17.9±0.2°, 18.9±0.2°, 19.4±0.2°, 21.5±0.2°, and 23.7±0.2°.
本发明涉及一种由式(I)表示的化合物或其药用可接受的盐和立体异构体,其中R1、R2、X、Y、P、W和Ar如描述中定义。本发明的式(I)化合物可用于制备用于治疗由多激酶异常介导的癌症的药物。还提供了一种晶型I的化合物4-(5-(2-氯苯基)-3-甲基-2,10-二氢吡唑并[4,3-b]吡啶并[4,3-e][1,4]二氮杂环-8-基)吗啡啶,其中在晶型I的X射线粉末衍射图样中,在7.4±0.20、17.9±0.2°、18.9±0.2°、19.4±0.2°、21.5±0.2°和23.7±0.2°处有特征峰。